Endothelin-1 in the Human Prostate: Tissue Levels, Source of Production and Isometric Tension Studies
- 1 August 1993
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 150 (2 Part 1) , 495-499
- https://doi.org/10.1016/s0022-5347(17)35534-9
Abstract
Endothelins mediate contractile responses in many types of vascular and nonvascular smooth muscle. The present study represents the first detailed characterization of endothelins in the human prostate. The objectives of this study were to determine the tissue levels and source of endogenous endothelin-1 (ET1) in the human prostate. The contractile effects of ET1 were also investigated using in vitro isometric tension studies. The mean tissue level of ET1 was 0.58 ± 0.08 pg./mg. tissue wet weight. Endothelin-like activity was markedly prominent in the glandular epithelium of the human prostate, whereas minimal endothelin-like activity was observed in the prostatic stroma. Strips of human prostatic tissue were suspended in isolated tissue chambers and challenged to a concentration response of ET1. The mean EC50 and Emax for ET1 was 3.2 × 10-8 M. and 0.12 ± 0.02 gm. force per mm.2 cross-sectional area (CSA), respectively. Preincubation with indomethacin, terazosin, or nifedipine did not alter the concentration-dependent response to ET1. A calcium-free buffer abolished the contractile response to ET1. Thus, ET1 mediates a potent contraction of human prostatic smooth muscle that is not mediated via alpha1 adrenergic or dihydropyridine sensitive calcium channels or prostaglandin synthesis. The presence of marked endothelin-like immunoreactivity strongly suggests a biological significance for endogenous endothelins in the human prostate.Keywords
This publication has 18 references indexed in Scilit:
- A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic HyperplasiaJournal of Urology, 1992
- Anti‐desmin vs. anti‐actin for quantifying the area density of prostate smooth muscleThe Prostate, 1992
- Use of an α1-Blocker, YM617, in the Treatment of Benign Prostatic HypertrophyJournal of Urology, 1990
- Medical outcomes research and benign prostatic hyperplasiaThe Prostate, 1990
- Potent contractile activity of endothelin on the human isolated urinary bladderBritish Journal of Pharmacology, 1989
- Contractile properties of human prostate adenomas and the development of infravesical obstructionThe Prostate, 1989
- Endothelin, a novel vasoconstrictor peptide, as potent brochoconstrictorEuropean Journal of Pharmacology, 1988
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988
- In vitro characterization of the α-adrenoceptors in human prostateEuropean Journal of Pharmacology, 1985
- The Development of Human Benign Prostatic Hyperplasia with AgeJournal of Urology, 1984